

Journal homepage: www.iberoamjmed.com

Original article

Fibrosis-4 index: A new marker to predict non-dipper blood pressure pattern in patients with newly diagnosed hypertension

Uğur Küçük ^{a,*}, Kadir Arslan ^a

^a Çanakkale Onsekiz Mart University, Faculty of Medicine, Department of Cardiology, Çanakkale, Turkey

ABSTRACT
Introduction: Epicardial fat tissue (EFT) is a significant risk factor for cardiovascular diseases.
This study aimed to investigate whether there is a relationship between the fibrosis-4 index
(FIB-4 index) and EFT in newly-diagnosed hypertensive patients and explore the usability of
the FIB-4 index in predicting non-dipper blood pressure (BP) pattern.
<u>Materials and methods</u> : Our case–control study consisted of 210 patients in 3 groups according to BP values, namely normotensive, dipper, and non-dipper groups. Transthoracic
echocardiography and 24-h ambulatory BP monitoring were performed in all patients.
Results: The median FIB-4 index was higher in the non-dipper group [1.56 (1.10-2)] than in
the dipper [1 (0.71-1.32)] and normotensive groups [0.96 (0.69-1.32)] (p < 0.001, for both). A
positive correlation was observed between EFT and the FIB-4 index (r=0.389, p<0.001). In
multivariate logistic regression analysis, EFT (odds ratio (OR): 0.506, 95% confidence interval
(CI): 1.288-2.135; p<0.001) and FIB-4 index (OR: 1.099, 95% CI: 1.621–5.556; p<0.001) were
found to be independent predictors of non-dipper BP. In the receiver operating characteristic curve analysis, the FIB-4 index had 68% sensitivity and 72% specificity at a value >1.25 (area under the curve: 0.751, 95%CI: 0.679-0.823, p<0.001).
Conclusions: In newly-diagnosed hypertensive people, the FIB-4 index is related to non-dipper
BP patterns. FIB-4 index appears to be a helpful tool in assessing risk associated with cardiovascular disease.

© 2022 The Authors. Published by Iberoamerican Journal of Medicine. This is an open access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).

https://doi.org/10.53986/ibjm.2022.0011

^{*} Corresponding author.

E-mail address: drugurkucuk@hotmail.com

 $ISSN: 2695-5075 \ / \ \odot \ 2022 \ The \ Authors. \ Published \ by \ Iberoamerican \ Journal \ of \ Medicine. \ This is an open \ access \ article \ under \ the \ CC \ BY \ license \ (http://creativecommons. \ org/licenses/by/4.0/).$

Índice de fibrosis-4: un nuevo marcador para predecir el patrón de presión arterial no dipper en pacientes con hipertensión recién diagnosticada

INFO. ARTÍCULO	RESUMEN
<i>Historia del artículo:</i> Recibido 29 Noviembre 2021 Recibido en forma revisada 26 Diciembre 2021 Aceptado 18 Enero 2022	Introducción: El tejido graso epicárdico (TGE) es un importante factor de riesgo de enfermedades cardiovasculares. Este estudio tuvo como objetivo investigar si existe una relación entre el índice de fibrosis-4 (índice FIB-4) y TGE en pacientes hipertensos recién diagnosticados y explorar la utilidad del índice FIB-4 para predecir la presión arterial (PA) no dipper. patrón. <u>Materiales y métodos</u> : Nuestro estudio de casos y controles consistió en 210 pacientes en 3
Palabras clave:	grupos según los valores de PA, a saber, grupos normotensos, dipper y no dipper. A todos los
Hipertensión	pacientes se les realizó ecocardiografía transtorácica y monitorización ambulatoria de la PA de
No-dipper	24 h.
Índice de fibrosis-4	<u>Resultados</u> : La mediana del índice FIB-4 fue mayor en el grupo no dipper [1,56 (1,10-2)] que
Tejido adiposo epicárdico	en los grupos dipper [1 (0,71-1,32)] y normotensos [0,96 (0,69-1,32)] (p<0.001, para ambos). Se observó una correlación positiva entre TGE y el índice FIB-4 (r = 0,389, p < 0,001). En análisis de regresión logística multivariante, EFT (odds ratio (OR): 0,506, intervalo de confianza (IC) 95%: 1,288-2,135; p<0,001) e índice FIB-4 (OR: 1,099, IC95%: 1,621-5,556; p<0,001) resultaron ser predictores independientes de PA no dipper. En el análisis de la curva
	característica operativa del receptor, el índice FIB-4 tuvo una sensibilidad del 68 % y una especificidad del 72 % a un valor >1,25 (área bajo la curva: 0,751, IC95%: 0,679-0,823, p<0,001).
	Conclusiones: En hipertensos de nuevo diagnóstico, el índice FIB-4 se relaciona con patrones
	de PA no dipper. El índice FIB-4 parece ser una herramienta útil para evaluar el riesgo asociado con la enfermedad cardiovascular.
	© 2022 Los Autores. Publicado por Iberoamerican Journal of Medicine. Éste es un artículo en acceso abierto
	bajo licencia CC BY (http://creativecommons. org/licenses/by/4.0/).
How to cite this article: K	üçük U, Arslan K. Fibrosis-4 index: A new marker to predict non-dipper blood pressure pattern in

patients with newly diagnosed hypertension. Iberoam J Med. 2022;4(1):52-59. doi: 10.53986/ibjm.2022.0011

1. INTRODUCTION

Hypertension (HT) is an important preventable risk factor for cardiovascular diseases [1]. An increase in the prevalence of HT is observed as a result of lack of physical activity, increases in life expectancy, and non-compliance with diet [2]. HT is defined as office systolic blood pressure (SBP) \geq 140 mmHg and diastolic blood pressure (DBP) \geq 90 mmHg [3]. According to the circadian rhythm, nighttime blood pressure (BP) values are expected to decrease by more than 10% on average compared with daytime BP values. Non-dipper BP is the absence of this decrease [4]. The presence of non-dipper BP pattern is an important risk factor for cardiovascular diseases (CVDs) [5].

Epicardial fat tissue (EFT) is a metabolically active organ and is a risk factor for CVDs [6]. EFT thickness is associated with coronary artery disease, atherosclerosis, and HT [7-9]. The fibrosis-4 index (FIB-4 index) is an easy parameter for assessing liver fibrosis. It consists of four parameters, liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase (AST)], age and platelet count, and is used in clinical conditions such as viral hepatitis and fatty liver disease not caused by alcohol [10, 11]. The FIB-4 index was associated to right ventricular dysfunction and poor cardiovascular outcomes in people without heart failure [12]. In another study, the FIB-4 index was shown to be associated with an increased risk of cardiovascular events and all-cause mortality in patients with atrial fibrillation (AF) [13].

In light of all this information, although EFT is known to be an important risk factor for CVD, there are no studies about whether there's a relationship between the FIB-4 index and EFT in newly-diagnosed HT patients, or whether the FIB-4 index can be used to predict non-dipper BP patterns. Therefore, the aim of our study was to investigate the relationship between the FIB-4 index and EFT in patients with newly-diagnosed HT and to investigate the usefulness of the FIB-4 index in predicting the non-dipper BP pattern.

2. MATERIALS AND METHODS

2.1. STUDY POPULATION

Our case–control study was conducted from September 2021 to April 2021 in Çanakkale Onsekiz Mart University Hospital, Turkey. A total of 210 patients were included in the study. The study included 140 patients with newly-diagnosed HT and 70 healthy volunteers of similar age and sex.

Patients with known coronary artery disease, heart failure (left ventricular ejection fraction >50%), a diagnosis of malignancy, chronic kidney disease, thyroid disease, body

mass index (BMI) \geq 30, liver disease or a history of treatment, alcohol use, cholesterol-lowering drug use, and those younger than 18 years of age were excluded. In addition, those who were previously diagnosed with hypertension or received medical treatment for BP control beforehand were not included in the study. BMI was represented in kg/m2.

Local ethics committee approval was obtained (decision no: 2011-KAEK-27/2021-2100083955). Our research was conducted in accordance with the Helsinki Declaration.

2.2. FIBROSIS-4 INDEX

The FIB-4 index is calculated as follows: it is obtained by dividing the value calculated by multiplying age (years) and AST (U/L) by the value obtained by multiplying ALT $(U/L)^{1/2}$ and platelet count $(10^9/L)$ [14].

FIB-4 index = age (years) × AST (U/L)/[ALT (U/L)^{1/2} × platelet count (10⁹/L)]

It has been shown in previous studies that EFT can be used as a predictor for non-dipper BP pattern in newly diagnosed, untreated hypertensive patients [15].

In our study, the diagnostic performance values of EFT and different variables were evaluated in predicting the nondipper blood pressure pattern in patients with newly diagnosed hypertension.

2.3. ECHOCARDIOGRAPHIC IMAGING PROTOCOL

All patients underwent transthoracic echocardiography. Echocardiographic examinations were performed using the Philips EPIQ 7 Ultrasound Machine (Philips EPIQ 7 Cardiac Ultrasound, Bothell, WA, USA) and a 2.5 MHz probe with simultaneous electrocardiography. A cardiologist who was blinded to the clinical features of the patients took echocardiographic measures on their left side with singlelead electrocardiography recording. The EFT thickness was measured by taking the average of three cardiac cycles perpendicularly between the echodense pericardium layer and the echolucent space on the right ventricular free wall at the end of systole in the parasternal long axis. The aortic annulus was considered a reference [16].

2.4. AMBULATORY BLOOD PRESSURE MONITORING

Hypertension was defined as SBP ≥140 mmHg and/or DBP \geq 90 mmHg measured during at least three office visits (3) measurements were made at 1 minute intervals at each visit and the average of the last 2 measurements was calculated) [17]. Ambulatory BP monitoring was applied for diurnal BP responses The patients were evaluated in terms of nondipper and dipper blood pressure. Ambulatory BP measurements were conducted using a Mobil-O-Graph (IEM, Stolberg, Germany) device. The recordings were taken over a period of 24 h. Measurements were taken every 15 minutes during the day (from 8 a.m. to 10 p.m.) and every 30 minutes during the night (from 10 p.m. to 8 a.m.). The patients were instructed to remain calm during the measurements. If more than 70% of the measurements were useable, it was considered a safe measurement. The mean 24-h systolic, diastolic and mean BP values of all patients were calculated. During night measurements, a decrease of <10% in SBP and DBP was defined as non-dipper BP, while a decrease of more than 10% was defined as dipper BP [18].

2.5. STATISTICAL ANALYSIS

Statistical analysis was performed using SPSS 20.0 (SPSS Inc, Chicago, IL, USA). The Kolmogorov-Smirnov test was used to evaluate the distribution of continuous variables. Quantitative variables are expressed as mean \pm SD. Data that did not conform to normal distribution are expressed as median and percentiles (25th and 75th percentiles). Percentages and numbers are used to express categorical variables. The Chi-square test was used when comparing the probability ratios of categorical variables. For the comparison of variables between groups, the Kruskal-Wallis test and Oneway Anova were used. In addition, Bonferroni's post hoc test was used. Spearman's correlation test was performed to analyze the correlation between EFT and the FIB-4 index. Multivariate logistic regression analysis was performed for independent predictors of the non-dipper BP pattern. Receiver operating characteristic (ROC) curve analysis was performed to determine the cutoff value for EFT thickness, the FIB-4 index, and the left ventricular mass index (LVMI). P values of <0.05 were

Table 1: Demographic and laboratory findings of patients						
Variable	Normotensive (n=70)	Dipper (n=70)	Non-Dipper (n=70)	P- value		
Age (years)	50.37±4.99	50.49±0.61	51.90±4.90	0.129		
Gender						
Male	38	48	42	0.219		
Female	32	22	28			
Smoking (n)	21	23	16	0.403		
Diabetes mellitus (n)	29	23	21	0.336		
BMI (kg/m ²)	26.00 (26.00-27.00)	27.00 (26.00-27.00)	27.00 (26.00-27.00)	0.549		
Heart rate, b.p.m	76.21±12.86	77.46±12.32	80.39±12.53	0.134		
Epicardial fat tissue (mm)	6.00 (5.00-8.00)	7.00 (6.00-7.00)	8.00 (7.00-9.00)	<0.001*		
Fibrosis-4 index	0.96 (0.69-1.32)	1.01 (0.71-1.32)	1.56 (1.10-2.00)	<0.001*		
In office SBP (mmHg)	111.00 (110.00-120.00)	146.00 (142.00-147.00)	149.00 (147.75-151.00)	<0.001*†¶		
In office DBP (mmHg)	75.00 (70.00-78.00)	87.00 (86.00-89.00)	92.00 (90.00-93.25)	<0.001* ^{†¶}		
Glucose (mg/dl)	102.00 (89.00-112.00)	99.50 (89.00-109.75)	101.00 (89.00-112.00)	0.747		
Creatinine (mg/dl)	0.93±0.17	0.93±0.14	0.94 ± 0.14	0.922		
AST (IU/L)	20.00 (18.00-22.00)	20.50 (18.00-25.00)	27.00 (25.00-28.00)	<0.001*¶		
ALT (IU/L)	ALT (IU/L) 25.00 (23.00-26.00)		25.00 (24.00-26.00)	0.473		
Hemoglobin (g/dl)	13.50±1.69	13.36±1.62	13.52±1.67	0.827		
Platelet count, 10 ³ /L	220.50 (168.26-269.50)	220.00 (166.00-269.50)	206.00 (168.25-261.00)	0.841		
LDL-C (mg/dl)	115.00 (100.00-145.25)	114.50 (99.00-146.00)	116.00 (99.75-146.00)	0.980		
HDL-C (mg/dl)	47.00 (40.00-55.00)	48.00 (40.00-55.00)	47.50 (40.00-55.00)	0.810		
Triglyceride (mg/dl)	98.00 (91.00-132.00)	98.00 (91.00-122.00)	98.00 (83.00-122.00)	0.460		

AST: Aspartate transaminase; ALT: Alanine aminotransferase; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol. *Normotensive vs dipper, †Normotensive vs Non-dipper, ¶Dipper vs Non-dipper.

considered statistically significant.

with newly-diagnosed HT (90 male, 50 female) and a control group (38 male, 32 female). The patient groups,

Table 2: Transthoracic echocardiographic and ambulatory blood pressure findings						
Variable	Dipper (n=70)	Non-Dipper (n=70)	P- value			
LVEDD (mm)	43.50 (41.00-46.00)	45.00 (43.00-46.25)	0.129			
LVESD (mm)	28.00 (26.75-30.00)	28.00 (27.00-31.00)	0.270			
LV ejection fraction (%)	57.00 (54.75-61.00)	58.00 (55.00-65.00)	0.219			
IVS thickness (mm)	12.00 (11.00-12.25)	12.00 (12.00-13.00)	0.001			
PW thickness (mm)	9.00 (8.00-10.25)	10.00 (9.00-11.00)	0.002			
LVMI (g/m ²⁾	155.94 ± 28.22	176.13±27.28	< 0.001			
Mitral E/A raito	0.98±0.12	1.03±0.12	0.017			
LA diameter (mm)	37.11±2.59	37.07±2.56	0.922			
RA diameter (mm)	31.26±2.47	31.50±2.29	0.548			
RV diameter (mm)	28.00 (27.00-30.25)	28.00 (27.00-30.00)	0.860			
TAPSE (mm)	19.09±2.67	19.93±2.77	0.069			
SPAB (mmHg)	20.21±2.40	21.54±2.46	0.002			
BP _s daytime (mm Hg)	146.00 (143.00-147.00)	150.00 (148.00-151.00)	< 0.001			
BP _d daytime (mm Hg)	87.00 (86.75-89.00)	92.00 (91.00-93.00)	< 0.001			
BP _s nighttime (mm Hg)	130.40 (127.70-131.30)	131.20 (129.50-132.12)	0.079			
BP _d nighttime (mm Hg)	77.30 (77.07-79.10)	78.80 (78.00-79.71)	0.001			
24-hour mean BP _s (mm Hg)	144.00 (141.00-145.00)	148.00 (146.00-149.00)	< 0.001			
24-hour mean BP _d (mm Hg)	85.50 (85.25-87.50)	90.50 (89.50-91.50)	< 0.001			

LVEDD: Left ventricular end diastolic diameter; LVESD: Left ventricular end systolic diameter; LV: Left ventricular; IVS: Interventricular septum; PW: Posterior wall; LVMI, Left ventricular mass index; LA: Left atrium; RA: Right atrium; TAPSE: Tricuspid Annular Systolic Excursion; SPA: Systolic Pulmonary Artery Pressure; BP_s: Systolic blood pressure; BP_d: Diastolic blood pressure.

3. RESULTS

The study included a total of 210 patients, including patients

which were initially divided into two main groups as patients with newly-diagnosed HT and the control group. Patients affected by HT were divided into two groups

Table 3: Independent factors of non-dipping blood pressure pattern				
Variable	Odds ratio	Standard Error	Confidence interval (95%)	P value
Age	0.031	0.038	0.958-1.110	0.413
Left ventricular mass index	0.019	0.006	1.006-1.031	0.003
Epicardial fat tissue	0.506	0.129	1.288-2.135	< 0.001
Fibrosis-4 index	1.099	0.315	1.621-5.561	< 0.001

(dipper and non-dipper BP patterns).

The clinical data for the study population are shown in Table 1. No differences were observed between the groups in terms of age, sex, diabetes mellitus (DM), BMI, and lipid panel results.

EFT and FIB-4 index values were numerically higher in the non-dipper group than in the dipper group, and this elevation was statistically significant (p < 0.001 for both, respectively). AST values were numerically higher in the non-dipper group than in the dipper group, and this elevation was statistically significant (p < 0.001) (Table 1). EFT and FIB-4 index values were not statistically significant in the normotensive compared to the dipper group (p = 0.600).

The echocardiographic and ambulatory blood pressure measurement results of the patients are shown in Table 2. The SBP and DBP values measured at night were statistically significantly different in patients with nondipper BP pattern compared to those with dipper BP pattern (p < 0.001, for both, respectively). In addition, the mean 24h SBP and DBP values were statistically more significant in patients with non-dipper BP pattern (p < 0.001, for both, respectively). While LVMI was 155.94 ± 28.22 in the group with dipper BP pattern, it was 176.13 ± 27.28 in the group with non-dipper BP pattern (p < 0.001) There were no differences in left ventricular systolic and diastolic diameters between dipper and non-dipper groups. However, interventricular septum and posterior wall thickness were found to be statistically and numerically significant in the non-dipper group (p = 0.001 and p = 0.002, respectively). The 24-hour mean systolic and diastolic blood pressure values were higher in the non-dipper group compared to the dipper group (p < 0.001, for both, respectively). (Table 2). In the correlation analysis, a positive correlation was observed between EFT and the FIB-4 index (r = 0.389, p < 0.001). In addition, a positive correlation was observed

between AST and LVMI (r = 0.308, p < 0.001).

The variables that were significant in univariate regression analysis were included in the logistic regression analysis. EFT (odds ratio (OR): 0.506, 95% confidence interval (CI): 1.288–2.135; p < 0.001), LVMI (OR: 0.019, 95% CI: 1.006–1.031; p = 0.003), and FIB-4 index (OR: 1.099, 95% CI: 1.621–5.556; p < 0.001) were evaluated as independent predictors of non-dipper BP (Table 3).

The diagnostic performance results of different variables in predicting the non-dipper blood pressure pattern in patients with newly diagnosed hypertension are shown in Table 4. We calculated the sensitivity and specificity of the EFT and FIB-4 index to predict non-dipper blood pressure pattern in patients with newly-diagnosed hypertension using ROC analysis. EFT values above 7.5 mm yielded 64% sensitivity and 76% specificity (area under the curve (AUC): 0.749, 95% CI: 0.678–0.819, p < 0.001). The FIB-4 index values >1.25 yielded 68% sensitivity and 72% specificity (AUC: 0.751, 95% CI: 0.679-0.823, p < 0.001). LVMI values >173.7 yielded 58% sensitivity and 77% specificity (AUC: 0.706, 95% CI: 0.630-0.781, p < 0.001). Fibrosis-4 index had the highest negative predictive value (Table 4) (Figure 1). Values were compared with high blood pressure diagnosis performed in ambulatory blood pressure measuring.

4. DISCUSSION

FIB-4 index and EFT thickness were investigated in this study, as well as the use of the FIB-4 index in predicting non-dipper BP pattern in patients with newly-diagnosed HT. To the best of our knowledge, this is the first study to examine the relationship between the FIB-4 index and EFT and evaluate the predictors of non-dipper BP pattern in patients with newly-diagnosed HT by evaluating both the

Table 4: ROC curve results for variables according to non-dipping pattern								
Variable	Diagnostic Scan				ROC Curve			
variable	Cut-off value	Sensitivity	Specificity	PPV	NPV	Area	95% CI	р
EFT	>7.5	64	76	56	80	0.749	0.678-0.819	< 0.001
Fibrosis-4 index	>1.25	68	72	55	82	0.751	0.679-0.823	< 0.001
LVMI	>173.7	58	77	56	78	0.706	0.630-0.781	< 0.001

LVMI, Left ventricular mass index; EFT: Epicardial fat tissue; PPV: Positive predictive value; NPV: Negative predictive value; CI: Confidence interval.




Figure 1: Receiver operator characteristic curve of the fibrosis-4 index to predict non-dipper blood pressure pattern in patients with newly diagnosed hypertension. Blue line: Epicardial fat tissue thickness; Green line: Fibrosis-4 index; Yellow line: Left ventricular mass index; Purple line: Reference line.

FIB-4 index and EFT together. Our study yielded some important results. First, a significant positive correlation was observed between the FIB-4 index and the EFT thickness in the patients with newly-diagnosed HT. Second, the FIB-4 index could be used to predict the non-dipper BP pattern in the patients with newly-diagnosed HT.

HT is associated with undesirable clinical outcomes such as stroke and heart attack [19]. In particular, the non-dipper BP pattern is an important risk factor for cardiovascular diseases [20], and methods for early diagnosis that ensure a diagnosis can be made in advance will play an important role in preventing undesirable cardiovascular outcomes.

EFT is the accumulation of visceral fat, which has the same circulation as the myocardium. It is not simple fat accumulation but is in fact an active organ that secretes proatherogenic cytokines such as proinflammatory cytokines and angiotensinogen [21]. In a study that included patients with LVEF >40%, it was shown that local EFT may cause structural changes in the myocardium and that localized EFT in the atrial region may be responsible for the increase in the incidence of AF [22]. In another recent study, it was shown that local EFT may play a role in the pathogenesis of ventricular arrhythmias originating from the right ventricular outflow tract [23,24]. EFT was associated with abnormal diurnal BP patterns [25]. As can be observed, EFT is associated with many clinical cardiovascular conditions. The results of our study showed that the

difference in the EFT thickness was numerically and statistically more significant in the group with non-dipper BP pattern compared with healthy individuals and the group with dipper BP pattern; in addition, the regression analysis showed that EFT was predictive of non-dipper BP.

The LVMI is used as a reliable measure of left ventricular hypertrophy (LVH). LVH results in hypertrophy of myocytes followed by collagen deposition in the interstitium of myocardial tissue. In the following period, fibrosis may occur in the myocardial tissue [26-28]. AST is highly active in the cytosol of myocardial tissue compared with serum, and its measurable values in the blood are expected to increase after fibrosis, which may occur in the presence of SVH [29]. Myocardial fibrosis is observed in multiple cardiac conditions including HT and aortic stenosis [30]. As a result of our study, LVMI and AST values were found to be significantly higher in the non-dipper pattern group compared with the normotensive and dipper BP pattern groups. The correlation analysis showed that there was a significant relationship between LVMI and AST, suggesting that the increase in AST is secondary to fibrosis after LVH. Sedentary lifestyle, obesity, autonomic dysfunction, and DM are important risk factors for non-dipper BP pattern [31-33]. Despite these findings, the mechanism of the nondipper BP pattern is unknown. As observed in our study, no differences were observed in the lipid levels, DM, and BMI between the group with non-dipper BP pattern and the group without non-dipper BP pattern. Therefore, the presence of an index such as the FIB-4 index, which can be used in the early detection of non-dipper BP pattern in clinical practice, may help in the early determination of CVD risk. Indeed, it was shown that the FIB-4 score can be used as a marker for the risk of developing heart failure in individuals without a history of cardiovascular disease [34].

Our study has a relatively small sample size; thus, largescale studies are required to determine the usefulness of the FIB-4 index in patients with newly-diagnosed HT. Although those with liver disease or a history of treatment were excluded from our study, it was impossible to definitively exclude liver pathologies because liver biopsy and computed tomography were not performed. Another shortcoming of our study is that cardiac magnetic resonance imaging was not performed for the assessment of cardiac fibrosis.

5. CONCLUSIONS

In patients with newly-diagnosed HT, the FIB-4 index is associated with non-dipper blood pressure. The increased FIB-4 index has predictive value for non-dipper BP and can be utilized as a useful and practical parameter in risk classification of patients with newly-diagnosed HT.

6. CONFLICT OF INTERESTS

The authors have no conflict of interest to declare. The authors declared that this study has received no financial support.

7. REFERENCES

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-88. doi: 10.1016/S0140-6736(18)32203-7.

2. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441-50. doi: 10.1161/CIRCULATIONAHA.115.018912.

3. O'Brien E, White WB, Parati G, Dolan E. Ambulatory blood pressure monitoring in the 21st century. J Clin Hypertens (Greenwich). 2018;20(7):1108-11. doi: 10.1111/jch.13275.

4. White WB. Ambulatory blood-pressure monitoring in clinical practice. N Engl J Med. 2003;348(24):2377-8. doi: 10.1056/NEJMp030057.

5. Mancia G, Di Rienzo M, Parati G. Ambulatory blood pressure monitoring use in hypertension research and clinical practice. Hypertension. 1993;21(4):510-24. doi: 10.1161/01.hyp.21.4.510.

6. Malavazos AE, Di Leo G, Secchi F, Lupo EN, Dogliotti G, Coman C, et al, Iacobellis G. Relation of echocardiographic epicardial fat thickness and myocardial fat. Am J Cardiol. 2010;105(12):1831-5. doi: 10.1016/j.amjcard.2010.01.368.

7. Ahn SG, Lim HS, Joe DY, Kang SJ, Choi BJ, Choi SY, et al. Relationship of epicardial adipose tissue by echocardiography to coronary artery disease. Heart. 2008;94(3):e7. doi: 10.1136/hrt.2007.118471.

8. Iacobellis G, Gao YJ, Sharma AM. Do cardiac and perivascular adipose tissue play a role in atherosclerosis? Curr Diab Rep. 2008;8(1):20-4. doi: 10.1007/s11892-008-0005-2.

9. Teijeira-Fernandez E, Eiras S, Grigorian-Shamagian L, Fernandez A, Adrio B, Gonzalez-Juanatey JR. Epicardial adipose tissue expression of adiponectin is lower in patients with hypertension. J Hum Hypertens. 2008;22(12):856-63. doi: 10.1038/jhh.2008.75.

10. Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci. 2011;56(10):3038-44. doi: 10.1007/s10620-011-1710-2.

11. Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2. doi: 10.1186/1471-230X-12-2.

12. Nakashima M, Sakuragi S, Miyoshi T, Takayama S, Kawaguchi T, Kodera N, et al. Fibrosis-4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction. ESC Heart Fail. 2021;8(3):2240-7. doi: 10.1002/ehf2.13317.

13. Saito Y, Okumura Y, Nagashima K, Fukamachi D, Yokoyama K, Matsumoto N, et al. Impact of the Fibrosis-4 Index on Risk Stratification of Cardiovascular Events and Mortality in Patients with Atrial Fibrillation: Findings from a Japanese Multicenter Registry. J Clin Med. 2020;9(2):584. doi: 10.3390/jcm9020584.

14. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25. doi: 10.1002/hep.21178.

15. Sengul C, Cevik C, Ozveren O, Duman D, Eroglu E, Oduncu V, et al. Epicardial fat thickness is associated with non-dipper blood pressure pattern in patients with essential hypertension. Clin Exp Hypertens. 2012;34(3):165-70. doi: 10.3109/10641963.2011.577488.

16. Iacobellis G, Willens HJ. Echocardiographic epicardial fat: a review of research and clinical applications. J Am Soc Echocardiogr. 2009;22(12):1311-9; quiz 1417-8. doi: 10.1016/j.echo.2009.10.013.

17. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-57. doi: 10.1161/HYPERTENSIONAHA.120.15026.

18. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. doi: 10.1093/eurheartj/ehy339.

19. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-20. doi: 10.1001/jama.2013.284427.

20. Ohkubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens. 2002;20(11):2183-9. doi: 10.1097/00004872-200211000-00017.

21. Talman AH, Psaltis PJ, Cameron JD, Meredith IT, Seneviratne SK, Wong DT. Epicardial adipose tissue: far more than a fat depot. Cardiovasc Diagn Ther. 2014;4(6):416-29. doi: 10.3978/j.issn.2223-3652.2014.11.05.

22. van Woerden G, van Veldhuisen DJ, Gorter TM, van Empel VPM, Hemels MEW, Hazebroek EJ, et al. Importance of epicardial adipose tissue localization using cardiac magnetic resonance imaging in patients with heart failure with mid-range and preserved ejection fraction. Clin Cardiol. 2021;44(7):987-93. doi: 10.1002/clc.23644.

23. Tanindi A, Erkan AF, Ekici B. Epicardial adipose tissue thickness can be used to predict major adverse cardiac events. Coron Artery Dis. 2015;26(8):686-91. doi: 10.1097/MCA.00000000000296.

24. Lu YY, Huang SY, Lin YK, Chen YC, Chen YA, Chen SA, et al. Epicardial adipose tissue modulates arrhythmogenesis in right ventricle outflow tract cardiomyocytes. Europace. 2021;23(6):970-7. doi: 10.1093/europace/euaa412.

25. Kim BJ, Cho KI, Choi JH, Park DH, Yu GI, Im SI, et al. Epicardial Fat Thickness and Neutrophil to Lymphocyte Ratio are Increased in Non-Dipper Hypertensive Patients. J Cardiovasc Ultrasound. 2016;24(4):294-302. doi: 10.4250/jcu.2016.24.4.294.

26. Laukkanen JA, Khan H, Kurl S, Willeit P, Karppi J, Ronkainen K, et al. Left ventricular mass and the risk of sudden cardiac death: a population-based study. J Am Heart Assoc. 2014;3(6):e001285. doi: 10.1161/JAHA.114.001285.

27. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83(6):1849-65. doi: 10.1161/01.cir.83.6.1849.

28. Halliday BP, Prasad SK. The Interstitium in the Hypertrophied Heart. JACC Cardiovasc Imaging. 2019;12(11 Pt 2):2357-68. doi: 10.1016/j.jcmg.2019.05.033.

29. Yöntem M, Erdoğdu B, Akdoğan M, Kaleli S. [The Importance of Cardiac Markers in Diagnosis of Acute Myocardial Infarction]. OTSBD. 2017;2(4):11-7.

30. Kwiecinski J, Lennen RJ, Gray GA, Borthwick G, Boswell L, Baker AH, et al. Progression and regression of left ventricular hypertrophy and myocardial fibrosis in a mouse model of hypertension and concomitant cardiomyopathy. J Cardiovasc Magn Reson. 2020;22(1):57. doi: 10.1186/s12968-020-00655-7.

31. Moczulska B, Zechowicz M, Leśniewska S, Osowiecka K, Gromadziński L. The Impact of Obesity on Nighttime Blood Pressure Dipping. Medicina (Kaunas). 2020;56(12):700. doi: 10.3390/medicina56120700.

32. Chen YK, Ni ZX, Li W, Xiao WM, Liu YL, Liang WC, et al. Diurnal Blood Pressure and Heart Rate Variability in Hypertensive Patients with Cerebral Small Vessel Disease: A Case-Control Study. J Stroke Cerebrovasc Dis. 2021;30(5):105673. doi: 10.1016/j.jstrokecerebrovasdis.2021.105673.

33. Lempiäinen PA, Vasunta RL, Bloigu R, Kesäniemi YA, Ukkola OH. Nondipping blood pressure pattern and new-onset diabetes in a 21-year follow-up. Blood Press. 2019;28(5):300-8. doi: 10.1080/08037051.2019.1615369.

34. Iwasaki Y, Shiina K, Matsumoto C, Nakano H, Fujii M, Yamashina A, et al. Correlation of the Fatty Liver Index with the Pathophysiological Abnormalities Associated with Cardiovascular Risk Markers in Japanese Men without any History of Cardiovascular Disease: Comparison with the Fibrosis-4 Score. J Atheroscler Thromb. 2021;28(5):524-34. doi: 10.5551/jat.56945.